Patents by Inventor Michael Etzerodt
Michael Etzerodt has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 8318679Abstract: The present invention relates to the design of trimeric polypeptides using polypeptide structural elements derived from the tetranectin protein family, and their use in rational de novo design and production of multi-functional molecules including the application of the multi-functional molecules in protein library technology, such as phage display technology, diagnostic and therapeutic systems, such as human gene therapy and imaging. The trimeric polypeptides being constructed as a monomer polypeptide construct comprising at least one tetranectin trimerising structural element (TTSE) which is covalently linked to at least one heterologous moiety, said TTSE being capable of forming a stable complex with two other TTSEs; or as an oligomer which is comprised of two monomer polypeptide constructs as mentioned above, and which comprises three TTSEs or a multiplum of three TTSEs, or which is comprised of three monomer polypeptide constructs.Type: GrantFiled: March 16, 2009Date of Patent: November 27, 2012Assignees: Anaphore, Inc., Hoffman-La Roche, Inc.Inventors: Hans Christian Thøgersen, Michael Etzerodt, Thor Las Holtet, Niels Jonas Heilskov Graversen, Jette Sandholm Kastrup, Bettina Bryde Nielsen, Ingrid Kjøller Larsen
-
Patent number: 8192953Abstract: The present invention relates to the design of trimeric polypeptides using polypeptide structural elements derived from the tetranectin protein family, and their use in rational de novo design and production of multi-functional molecules including the application of the multi-functional molecules in protein library technology, such as phage display technology, diagnostic and therapeutic systems, such as human gene therapy and imaging. The trimeric polypeptides being constructed as a monomer polypeptide construct comprising at least one tetranectin trimerising structural element (TTSE) which is covalently linked to at least one heterologous moiety, said TTSE being capable of forming a stable complex with two other TTSEs; or as an oligomer which is comprised of two monomer polypeptide constructs as mentioned above, and which comprises three TTSEs or a multiplum of three TTSEs, or which is comprised of three monomer polypeptide constructs.Type: GrantFiled: March 16, 2009Date of Patent: June 5, 2012Assignees: Anaphore, Inc., Hoffmann-La Roche, Inc.Inventors: Hans Christian Thøgersen, Michael Etzerodt, Thor Las Holtet, Niels Jonas Heilskov Graversen, Jette Sandholm Kastrup, Bettina Bryde Nielsen, Ingrid Kjøller Larsen
-
Publication number: 20120094873Abstract: Novel polypeptides having the scaffold structure of a C-type lectin-like domain (CTLD) and a randomized loop region for specifically binding a variety of target compounds and also provides nucleic acids encoding the polypeptides. Combinatorial CTLD libraries, methods for constructing the libraries, and methods for screening the libraries to identify and isolate the novel CTLD polypeptides. Libraries of nucleic acids encoding polypeptides having a scaffold CTLD with a randomized loop region, as well as nucleic acid sequences, vectors, and methods for preparing and expressing the libraries. Exemplary nucleic acids useful in the combinatorial libraries are derived from tetranectin and other proteins having a CTLD.Type: ApplicationFiled: June 8, 2011Publication date: April 19, 2012Applicant: ANAPHORE, INC.Inventors: Michael Etzerodt, Thor Las Holtet, Niels Jonas Heilskov Graversen, Hans Christian Thøgersen
-
Patent number: 8017559Abstract: The present invention provides novel polypeptides having the scaffold structure of a C-type lectin-like domain (CTLD) and a randomized loop region for specifically binding a variety of target compounds and also provides nucleic acids encoding the polypeptides. The present invention further provides combinatorial CTLD libraries, methods for constructing the libraries, and methods for screening the libraries to identify and isolate the novel CTLD polypeptides. Specifically, the invention provides libraries of nucleic acids encoding polypeptides having a scaffold CTLD with a randomized loop region, as well as nucleic acid sequences, vectors, and methods for preparing and expressing the libraries. Exemplary nucleic acids useful in the combinatorial libraries are derived from tetranectin and other proteins having a CTLD.Type: GrantFiled: December 4, 2006Date of Patent: September 13, 2011Assignee: Anaphore, Inc.Inventors: Michael Etzerodt, Thor Las Holtet, Niels Jonas Heilskov Graversen, Hans Christian Thøgersen
-
Publication number: 20110027267Abstract: Fusion proteins having sequences that target specific moieties such as carbohydrates, lipids, and/or proteins that are associated with certain cell types and/or pathogens; and a sequence that induces effector function are provided. The disclosure also provides nucleic acids encoding the fusion proteins, as well as pharmaceutical compositions, methods of use, and methods of treating conditions or diseases such as infectious diseases, cancers, immune related disorders and other ailments, that include the fusions proteins described herein.Type: ApplicationFiled: November 10, 2008Publication date: February 3, 2011Applicant: ANAPHORE, INC.Inventors: Majbritt Hauge Kyneb, Mikkel Holmen Andersen, Michael Etzerodt, Thor Las Holtet
-
Publication number: 20100048879Abstract: There are provided multimeric fusion proteins exhibiting anti-viral activity. The fusion proteins comprise the HR2 region of the ectodomain of the human immunodeficiency virus gp41 protein which is fused to a multimerisation domain peptide such as a trimerisation domain derived from tetranectin. The multimerised fusion proteins may be used as HIV fusion inhibitors in the treatment of AIDS.Type: ApplicationFiled: January 16, 2008Publication date: February 25, 2010Applicant: BOREAN PHARMA APSInventor: Michael ETZERODT
-
Publication number: 20100028995Abstract: Tetranectin trimerizing polypeptides and fusion proteins including the polypeptides and therapeutic polypeptides and proteins. Trimeric complexes of the polypeptides and fusion proteins. Pharmaceutical compositions of the polypeptides, fusion proteins and the trimeric complexes.Type: ApplicationFiled: April 8, 2009Publication date: February 4, 2010Inventors: Jonas Heilskov Graversen, Hans Christian Thøgersen, Anke Kretz-Rommel, Michael Etzerodt, Thor Las Holtet, Mikkel Holmen Andersen, John Nieland
-
Publication number: 20100022756Abstract: The present invention relates to the design of trimeric polypeptides using polypeptide structural elements derived from the tetranectin protein family, and their use in rational de novo design and production of multi-functional molecules including the application of the multi-functional molecules in protein library technology, such as phage display technology, diagnostic and therapeutic systems, such as human gene therapy and imaging. The trimeric polypeptides being constructed as a monomer polypeptide construct comprising at least one tetranectin trimerising structural element (TTSE) which is covalently linked to at least one heterologous moiety, said TTSE being capable of forming a stable complex with two other TTSEs; or as an oligomer which is comprised of two monomer polypeptide constructs as mentioned above, and which comprises three TTSEs or a multiplum of three TTSEs, or which is comprised of three monomer polypeptide constructs.Type: ApplicationFiled: March 16, 2009Publication date: January 28, 2010Applicants: HOFFMAN-LAROCHE, INC., ANAPHORE, INC.Inventors: Hans Christian Thogersen, Michael Etzerodt, Thor Las Holtet, Niels Jonas Heilskov Graversen, Jette Sandholm Kastrup, Bettina Bryde Nielsen, Ingrid Kjoller Larsen
-
Publication number: 20100003719Abstract: The present invention relates to the design of trimeric polypeptides using polypeptide structural elements derived from the tetranectin protein family, and their use in rational de novo design and production of multi-functional molecules including the application of the multi-functional molecules in protein library technology, such as phage display technology, diagnostic and therapeutic systems, such as human gene therapy and imaging. The trimeric polypeptides being constructed as a monomer polypeptide construct comprising at least one tetranectin trimerising structural element (TTSE) which is covalently linked to at least one heterologous moiety, said TTSE being capable of forming a stable complex with two other TTSEs; or as an oligomer which is comprised of two monomer polypeptide constructs as mentioned above, and which comprises three TTSEs or a multiplum of three TTSEs, or which is comprised of three monomer polypeptide constructs.Type: ApplicationFiled: March 16, 2009Publication date: January 7, 2010Applicants: HOFFMAN-LAROCHE, INC., ANAPHORE, INC.Inventors: Hans Christian Thagersen, Michael Etzerodt, Thor Las Holtet, Niels Jonas Heilskov Graversen, Jette Sandholm Kastrup, Bettina Bryde Nielsen, Ingrid Kjoller Larsen
-
Patent number: 7642044Abstract: The present invention relates to the design of trimeric polypeptides using polypeptide structural elements derived from the tetranectin protein family, and their use in rational de novo design and production of multi-functional molecules including the application of the multi-functional molecules in protein library technology, such as phage display technology, diagnostic and therapeutic systems, such as human gene therapy and imaging. The trimeric polypeptides being constructed as a monomer polypeptide construct comprising at least one tetranectin trimerising structural element (TTSE) which is covalently linked to at least one heterologous moiety, said TTSE being capable of forming a stable complex with two other TTSEs; or as an oligomer which is comprised of two monomer polypeptide constructs as mentioned above, and which comprises three TTSEs or a multiplum of three TTSEs, or which is comprised of three monomer polypeptide constructs.Type: GrantFiled: June 14, 2006Date of Patent: January 5, 2010Assignees: Anaphore, Inc., Hoffman-La Roche, Inc.Inventors: Hans Christian Thogersen, Michael Etzerodt, Thor Las Holtet, Niels Jonas Heilskov Graversen, Jette Sandholm Kastrup, Bettina Bryde Nielsen, Ingrid Kjoller Larsen
-
Publication number: 20070275393Abstract: A novel family of protein libraries comprising CTLDs (C-type Lectin-Like Domains) in which internal polypeptide loop-regions lining the ligand binding sites in CTLDs have been replaced with ensembles of completely or partially randomised polypeptide segments. Tetranectin CTLDs were chosen as framework for the preferred embodiment of the invention; and versatile phagemid vectors useful in the generation and manipulation of human and murine tetranectin CTLD libraries are disclosed as part of this invention. Tetranectin CTLDs in monomeric as well as in trimeric form are efficiently displayed as gene III fusions in fully functional form by the recombinant fd phage display vector. CTLD derivatives with affinity for new ligands may readily be isolated from libraries of vectors displaying CTLDs, in which loop-regions have been randomised, using one or more rounds of enrichment by screening or selection followed by amplification of the enriched subpopulation in each round.Type: ApplicationFiled: December 4, 2006Publication date: November 29, 2007Inventors: Michael Etzerodt, Thor Holtet, Niels Graversen, Hans Thogersen
-
Publication number: 20070154901Abstract: The present invention relates to the design of trimeric polypeptides using polypeptide structural elements derived from the tetranectin protein family, and their use in rational de novo design and production of multi-functional molecules including the application of the multi-functional molecules in protein library technology, such as phage display technology, diagnostic and therapeutic systems, such as human gene therapy and imaging. The trimeric polypeptides being constructed as a monomer polypeptide construct comprising at least one tetranectin trimerising structural element (TTSE) which is covalently linked to at least one heterologous moiety, said TTSE being capable of forming a stable complex with two other TTSEs; or as an oligomer which is comprised of two monomer polypeptide constructs as mentioned above, and which comprises three TTSEs or a multiplum of three TTSEs, or which is comprised of three monomer polypeptide constructs.Type: ApplicationFiled: June 14, 2006Publication date: July 5, 2007Applicant: PROTEIN ENGINEERING TECHNOLOGY APSInventors: Hans Thogersen, Michael Etzerodt, Thor Holtet, Niels Graversen, Jette Kastrup, Bettina Nielsen, Ingrid Larsen
-
Publication number: 20050202043Abstract: There are provided multimeric fusion proteins exhibiting anti-viral activity. The fusion proteins comprise the HR2 region of the ectodomain of the human immunodeficiency virus gp41 protein which is fused to a multimerisation domain peptide such as a trimerisation domain derived from tetranectin. The multimerised fusion proteins may be used as HIV fusion inhibitors in the treatment of AIDS.Type: ApplicationFiled: February 23, 2005Publication date: September 15, 2005Applicant: Borean Pharma A/SInventor: Michael Etzerodt
-
Publication number: 20040132094Abstract: A novel family of protein libraries comprising CTLDs (C-type Lectin-Like Domains) in which internal polypeptide loop-regions lining the ligand binding sites in CTLDs have been replaced with ensembles of completely or partially randomised polypeptide segments. Tetranectin CTLDs were chosen as framework for the preferred embodiment of the invention; and versatile phagemid vectors useful in the generation and manipulation of human and murine tetranectin CTLD libraries are disclosed as part of this invention. Tetranectin CTLDs in monomeric as well as in trimeric form are efficiently displayed as gene III fusions in fully functional form by the recombinant fd phage display vector. CTLD derivatives with affinity for new ligands may readily be isolated from libraries of vectors displaying CTLDs, in which loop-regions have been randomised, using one or more rounds of enrichment by screening or selection followed by amplification of the enriched subpopulation in each round.Type: ApplicationFiled: June 13, 2003Publication date: July 8, 2004Inventors: Michael Etzerodt, Thor Las, Niels Jonas Heilskov Graversen, Hans Christian
-
Patent number: 5917018Abstract: A novel, generally applicable method for producing correctly folded proteins from a mixture of misfolded proteins, e.g. bacterial inclusion-body aggregates. A major new aspect of the method is that over-all efficiency is achieved by subjecting proteins to a time-sequence of multiple denaturation-renaturation cycles, resulting in gradual accumulation of the correctly folded protein. The method has proven efficient for a variety of recombinant proteins. Also provided are novel encrypted recognition sites for bovine coagulation factor X.sub.a. The encrypted recognition sites described may be activated in vitro by controlled oxidation or by reversible derivatization of cysteine residues and thereby generate new cleavage sites for factor X.sub.a. Two new recombinant serine protease exhibiting narrow substrate specificity for factor X.sub.a recognition sites are also provided. They may replace natural coagulation factor X.sub.a for cleavage of chimeric proteins.Type: GrantFiled: September 18, 1995Date of Patent: June 29, 1999Assignee: Denzyme APSInventors: Christian Th.o slashed.gersen, Thor Las Holtet, Michael Etzerodt
-
Patent number: 5739281Abstract: A novel, generally applicable method for producing correctly folded proteins from a mixture of misfolded proteins, e.g. bacterial inclusion-body aggregates. A major new aspect of the method is that over-all efficiency is achieved by subjecting proteins to a time-sequence of multiple denaturation-renaturation cycles, resulting in gradual accumulation of the correctly folded protein. The method has proven efficient for a variety of recombinant proteins. Also provided are novel encrypted recognition sites for bovine coagulation factor X.sub.a. The encrypted recognition sites described may be activated in vitro by controlled oxidation or by reversible derivatization of cysteine residues and thereby generate new cleavage sites for factor X.sub.a. Two new recombinant serine protease exhibiting narrow substrate specificity for factor X.sub.a recognition sites are also provided. They may replace natural coagulation factor X.sub.a for cleavage of chimeric proteins.Type: GrantFiled: June 6, 1995Date of Patent: April 14, 1998Assignee: Denzyme APSInventors: Hans Christian Th.o slashed.gersen, Thor Lns Holtet, Michael Etzerodt